Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

Solid Tumors and Lymphomas Clinical Trial

Official title:

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) as a Monotherapy in Subjects With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Subjects With Estrogen Receptor Positive Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02392611
• Other study ID #: GS-US-350-1599
• Secondary ID: 2016-001912-39
• Status: Completed
• Phase: Phase 1
• Start date: March 16, 2015
• Est. completion date: October 11, 2017

Study information

• Verified date: December 2020
• Source: Gilead Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objectives of this study are to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or recommended dose for phase 2 study (RDP2) of alobresib as a monotherapy in participants with advanced solid tumors and lymphomas, and in combination with exemestane or fulvestrant in participants with advanced estrogen receptor positive breast cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: October 11, 2017
• Est. primary completion date: October 11, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

• Group 1: Histologically or cytologically confirmed advanced malignant solid tumor or lymphoma (any subtype) that is refractory to or intolerant of standard therapy or for which no standard therapy is available

• Group 2: Post-menopausal women with advanced stage estrogen receptor positive breast cancer who are candidates for exemestane or fulvestrant

• Group 3: Individuals with lymphoma are limited to diffuse large B-cell lymphoma and peripheral T-cell lymphoma that are refractory to or intolerant of standard therapy or for which no standard therapy is available

• Eastern Cooperative Oncology Group (ECOG) Performance Status of = 1

• Adequate organ function defined as follows:

• Hematologic: Platelets = 100 x 10^9/L; Hemoglobin = 9.0 g/ dL; Absolute neutrophil count (ANC) = 1.5 x 10^9/L (without platelet transfusion or any growth factors within previous 7 days of the hematologic laboratory values obtained at screening visit). Participants in the Group 3 lymphoma expansion may be enrolled with an ANC of = 1.0 x 10^9 /L; Platelets = 75 x 10^9 /L.

• Hepatic: Aspartate transaminase (AST) / Alanine transaminase (ALT) = 2.5 x upper limit of normal (ULN) (if liver metastases are present, = 5 x ULN); Total or conjugated bilirubin = 1.5 x ULN

• Renal: Serum creatinine = 1.5 x ULN or creatinine clearance (CrCl) = 60 ml/min as calculated by the cockcroft-gault method

• Coagulation: International Normalized Ratio (INR) = 1.2

Key Exclusion Criteria:

• Known brain metastasis or leptomeningeal disease

• Myocardial infarction, symptomatic congestive heart failure (New York Heart Association Classification > Class II), unstable angina, or serious uncontrolled cardiac arrhythmia within the last 6 months of study Day 1

• Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (ie, larger than what is required for placement of central venous access, percutaneous feeding tube, or biopsy) within 28 days of first dose of study drug

• History of long QT syndrome or whose corrected QT interval (QTc) measured (Fridericia method) at screening is prolonged (> 450 ms for males and > 470 ms for females). Individuals who screen-fail due to this criterion are not eligible to be re-screened

• Clinically significant bleeding within 28 days of study Day 1

• Known human immunodeficiency virus (HIV) infection

• Hepatitis B surface antigen positive

• Hepatitis C virus (HCV) antibody positive

• No active anticoagulation within 7 days of study Day 1; including acetylsalicylic acid, low molecular weight heparin, or warfarin.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Related Conditions & MeSH terms

• Lymphoma
• Solid Tumors and Lymphomas

Intervention

Drug:
• Alobresib
Tablet administered orally once daily on Study Day 1 through Cycle 1 Day 28 of 28 days cycle
• Exemestane
Tablets administered orally once daily on Cycle 1 Day 1 of 28 days cycle
• Fulvestrant
Administered intramuscularly on Cycle 1 Day 1 of 28 days cycle and every 28 days

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Gilead Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Experiencing Dose Limiting Toxicities (DLTs)	A DLT was a toxicity, considered possibly related to alobresib, and which occurred during DLT assessment window (Day 1 through Cycle 1 Day 28) in each cohort: Grade = 4 neutropenia (absolute neutrophil count [ANC] < 500/mm^3); Grade =3 neutropenia (ANC< 1000/mm^3) with fever (a single temperature of > 38.3°C or a sustained temperature of = 38°C for more than 1 hour [hr]); Grade = 3 thrombocytopenia; Grade = 2 bleeding; Grade = 3 non hematologic toxicity, except Grade 3 nausea or emesis with maximum duration of 48 hrs on adequate medical therapy and Grade 3 diarrhea which persists for < 72 hrs in absence of maximal medical therapy; Grade = 2 non hematologic treatment-emergent adverse event (TEAE) of potential clinical significance; treatment interruption = 7 days due to unresolved toxicity; and any Grade 3 or 4 elevation in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) associated with a Grade 2 elevation in bilirubin that is at least possibly related to alobresib.	Baseline (Day 1) up to 28 days
Secondary	Pharmacokinetic (PK) Parameter: Cmax of Alobresib	Cmax is defined as the maximum concentration of the drug.	Cycle 1: Predose (0 hr), 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hrs postdose on Days 1 and 8 (1 Cycle = 28 days)
Secondary	PK Parameter: Ctau of Alobresib	Ctau is defined as the observed drug concentration at the end of the dosing interval.	Cycle 1: Predose (0 hr), 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hrs postdose on Day 8 (1 Cycle = 28 days)
Secondary	PK Parameter: AUC0-24 of Alobresib	AUC0-24 is defined as the concentration of drug over time from time zero to time 24 hrs.	Cycle 1: Predose (0 hr), 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hrs postdose on Days 1 and 8 (1 Cycle = 28 days)
Secondary	PK Parameter: AUCtau of Alobresib	AUCtau is defined as the concentration of drug over time (the area under the concentration verses time curve over the dosing interval).	Cycle 1: Predose (0 hr), 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hrs postdose on Day 8 (1 Cycle = 28 days)
Secondary	PK Parameter: Tmax of Alobresib	Tmax is defined as the time (observed time point) of Cmax.	Cycle 1: Predose (0 hr), 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hrs postdose on Days 1 and 8 (1 Cycle = 28 days)
Secondary	PK Parameter: t1/2 of Alobresib	t1/2 is defined as the estimate of the terminal elimination half-life of the drug. Due to short sampling period of the terminal elimination phase in these cohorts t1/2 values should be interpreted with caution.	Cycle 1: Predose (0 hr), 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hrs postdose on Days 1 and 8 (1 Cycle = 28 days)